openPR Logo
Press release

Investigation announced for Investors in shares of Ascendis Pharma A/S (NASDAQ: ASND) over potential Wrongdoing

06-14-2023 02:25 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Ascendis Pharma A/S (NASDAQ: ASND) shares over potential wrongdoing.

An investigation on behalf of investors in Ascendis Pharma A/S (NASDAQ: ASND) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Ascendis Pharma A/S.

Investors who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Ascendis Pharma A/S directors breached their fiduciary duties and caused damage to the company and its shareholders.

Denmark based Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Ascendis Pharma A/S reported that its annual Total Revenue rose from 7.77 million EUR in 2021 to 51.17 million EUR in 2022, and that its Net Loss increased from 383.57 million EUR in 2021 to 583.19 million EUR in 2022.

On April 3, 2023, before market hours, Ascendis Pharma A/S announced that the "U.S. Food & Drug Administration ("FDA") has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application ("NDA") for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter."

Shares of Ascendis Pharma A/S (NASDAQ: ASND) declined from $134.52 per share in November 11, 2022, to as low as $64.33 per share on April 3, 2023.

Those who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Ascendis Pharma A/S (NASDAQ: ASND) over potential Wrongdoing here

News-ID: 3087475 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Ascendis

Parathyroid Disorders Market Booming Worldwide with Hormonal Therapy Advancement …
Parathyroid Disorders Market Insights The Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032. Coherent Market Insights has released a detailed analysis of the Parathyroid Disorders Market (2025-2032), focusing on the evolving U.S. healthcare landscape. The report presents critical metrics such as market
Achondroplasia Market: Epidemiology, Therapies, Companies, DelveInsight | Ascend …
Achondroplasia therapies, such as VOXZOGO (vosoritide), RBM-007, SAR-442501, Low dose infigratinib, and others, are expected to boost the Achondroplasia Market in the upcoming years. DelveInsight has launched a new report on "Achondroplasia - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and
Hypoparathyroidism Market Growth Anticipated by 2034, DelveInsight | Companies: …
Rising cases of hypoparathyroidism across different regions are driving the demand for advanced diagnostic and treatment options in the hypoparathyroidism market. This growing need is contributing to the overall expansion of the market. The Hypoparathyroidism Market Report 2034 [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] by DelveInsight provides an in-depth analysis of current treatment practices for hypoparathyroidism, upcoming drugs in the pipeline, market shares of individual therapies, and forecasts the growth trajectory of the hypoparathyroidism market from
Hypoparathyroidism Market Growth Anticipated by 2034 | Companies includes Takeda …
Rising cases of hypoparathyroidism across different regions are driving the demand for advanced diagnostic and treatment options in the hypoparathyroidism market. This growing need is contributing to the overall expansion of the market. The Hypoparathyroidism Market Report 2034 [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] by DelveInsight provides an in-depth analysis of current treatment practices for hypoparathyroidism, upcoming drugs in the pipeline, market shares of individual therapies, and forecasts the growth trajectory of the hypoparathyroidism market from
Hypoparathyroidism Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoparathyroidism Market Forecast https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Hypoparathyroidism
Adult Growth Hormone Deficiency Market to Witness Growth by 2032 | Companies- No …
DelveInsight's "Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Adult Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Adult Growth Hormone Deficiency market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and